Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

ACC pipeline

Response and survival, trial by trial.

Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.

18 arms have a reported figure.

Amivantamab 1

Amivantamab

Amivantamab

not stated in source · Single arm

ACC (n = 21)

responders: 1 patients (of 21), results posted 05.08.2026

median progression-free survival: 4.6 months, results posted 05.08.2026

Amivantamab in ACC · NCT05074940

Axitinib (off Label) 5

Axitinib (off Label)

Axitinib 5 mg twice daily

5 mg · ITT

R/M ACC with progression within 9 months (n = 60 total)

Comparator: observation

median progression-free survival: 10.8 months, primary analysis

6-month progression-free survival: 73%, 6 months

progression-free survival hazard ratio vs observation: 0.25 HR, as reported in ESMO-EURACAN guideline

objective response rate: 0%, primary analysis

disease control rate: 100%, primary analysis

Axitinib vs observation (randomized Phase 2) · NCT02859012

Axitinib (off Label)

Observation

none · ITT

R/M ACC with progression within 9 months

median progression-free survival: 2.8 months, primary analysis

6-month progression-free survival: 23%, 6 months

disease control rate: 51.9%, primary analysis

median overall survival: 27.2 months, axitinib median not reached; P 0.226

Axitinib vs observation (randomized Phase 2) · NCT02859012

Axitinib (off Label)

Axitinib + avelumab

axitinib 5 mg twice daily + avelumab · Single arm

R/M ACC (n = 28 evaluable)

confirmed objective response rate: 18%, primary analysis

median progression-free survival: 7.3 months, primary analysis

median overall survival: 16.6 months, primary analysis

Axitinib + avelumab Phase 2 (MD Anderson)

Emiltatug Ledadotin (Emi-Le, XMT-1660) 2

Lenvatinib (off Label) 3

Lenvatinib (off Label)

Lenvatinib 24 mg

24 mg · Single arm

progressive R/M ACC (n = 32 evaluable)

objective response rate: 15.6%, primary analysis

median progression-free survival: 17.5 months, 8 progression events

Lenvatinib MSK Phase 2 · NCT02780310

Lenvatinib (off Label)

Lenvatinib 24 mg

24 mg · Single arm

R/M salivary ACC (n = 26 evaluable)

objective response rate: 11.5%, primary analysis

median progression-free survival: 9.1 months, primary analysis

median overall survival: 27 months, primary analysis

ACC-LEN14 · NCT02860936

Osugacestat (AL101, BMS-906024) 2

Osugacestat (AL101, BMS-906024)

AL101 4 mg

4 mg · Single arm

R/M ACC with NOTCH1 to 4 activating mutation (n = 45)

responders (CR or PR): 3 patients (of 45), final, results posted 01.31.2024

median overall survival: 9.3 months, final

ACCURACY · NCT03691207

Osugacestat (AL101, BMS-906024)

AL101 6 mg

6 mg · Single arm

R/M ACC with NOTCH activating mutation (n = 42)

responders (CR or PR): 2 patients (of 42), final

median overall survival: 9.4 months, final

ACCURACY · NCT03691207

Regorafenib (off Label) 1

REM-422 2

REM-422

REM-422 24 mg (RP2D), biomarker positive

24 mg · Single arm

R/M ACC, MYB biomarker positive at RP2D (n = 7)

objective response rate: 43%, cutoff 01.07.2026, Abstract 6009 states 42% (3 of 7)

disease control rate: 100%, ASCO 2026

ARIA · NCT06118086

REM-422

REM-422 12 mg or more, biomarker positive

12 to 48 mg · Single arm

biomarker-positive R/M ACC (n = 30)

any target-lesion reduction: 70%, cutoff 01.07.2026

target-lesion shrinkage of 20% or more: 47%, cutoff 01.07.2026

ARIA · NCT06118086

RGT-61159 1

RGT-61159

RGT-61159 at or below RP2D

at or below RP2D (mixed doses) · Single arm

R/R ACC, evaluable (n = 39)

disease control rate: 84.6%, ASCO 2026, preliminary

partial responses: 3 patients (of 39), ASCO 2026; 2 confirmed, 1 pending

RGT-61159 Phase 1a/b · NCT06462183

Rivoceranib 1

Rivoceranib

Rivoceranib 700 mg

700 mg · Single arm

R/M ACC (n = 80; 72 evaluable)

objective response rate (investigator): 15.3%, primary analysis

objective response rate (independent review): 9.7%, primary analysis

median progression-free survival: 9 months, primary analysis

median duration of response (investigator): 14.9 months, primary analysis

Rivoceranib Phase 2 · NCT04119453

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.